Clinical Study

A Phase III Study Of Postoperative Radiation Therapy (Imrt) +/- Cetuximab For Locally-Advanced Resected Head And Neck Cancer

Posted Date: Jan 10, 2018

  • Investigator: Kevin Redmond
  • Specialties: Hematology/Oncology, Oncology, Otolaryngology, Radiation Oncology, Surgical Oncology
  • Type of Study: Drug

This study will compare the good and bad effects of radiation therapy alone with radiation therapy and cetuximab to find out which is better. Cetuximab is a drug that may delay or prevent tumor growth by blocking certain cellular chemical pathways that lead to tumor development. Follow-up visits will continue indefinitely. Approximately 700 people will participate in this study with 5 participating locally.

Criteria:

Eligible Patients Must Have Head And Neck Cancer That After Surgery Has An Intermediate Risk Of Recurring

Keywords:

Head And Neck Cancer, R0920, Recurrent, Resected, Null

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu